Pfizer Raises Estimates for COVID Vax Sales by $2B
The company maintained its full-year sales forecast for COVID-19 pill Paxlovid at $22 billion.
Pfizer and Moderna have rolled out an Omicron-tailored booster dose in Europe and the United States.
It reported third-quarter sales of $22.60 billion, beating the average analyst estimate of $21.04 billion, according to IBES data from Refinitiv .
Pfizer Raises Estimates for COVID Vax Sales by $2B.
The company maintained its full-year sales forecast for COVID-19 pill Paxlovid at $22 billion.
Pfizer and Moderna have rolled out an Omicron-tailored booster dose in Europe and the United States.
It reported third-quarter sales of $22.60 billion, beating the average analyst estimate of $21.04 billion, according to IBES data from Refinitiv.
